Table 3.
Age, gender and cancer characteristics.
| Total cohort | Test completed | Contra-indicated | Deferred | ||||
|---|---|---|---|---|---|---|---|
| At pace | Slower self-paced | Shorter self-paced | Flat self-paced | ||||
|
Cancer survivors Number (%) |
169 (100) | 88 (52) | 24 (14) | 21 (12) | 9 (5) | 20 (12) | 7 (4) |
| Age at clinic presentationa, years mean ± SEM (range) | 53 ± 1 (27–79) | 49 ± 1 (27–66) | 56 ± 2 (38–74) | 60 ± 2 (39–77) | 65 ± 3 (54–76) | 58 ± 3 (35–79) | 43 ± 2 (37–51) |
| Age at cancer diagnosisb, years mean ± SEM (range) | 51 ± 1 (26–78) | 47 ± 1 (26–64) | 54 ± 2 (29–74) | 59 ± 2 (38–76) | 63 ± 3 (50–76) | 56 ± 3 (35–78) | 40 ± 2 (34–46) |
| Years post cancer diagnosis, mean ± SEM (range) | 1.8 ± 0.2 (0–26) | 1.7 ± 0.4 (0–26) | 2.1 ± 0.7 (0–13) | 2.1 ± 1.0 (0–22) | 1.9 ± 0.8 (0–8) | 1.4 ± 0.4 (0–6) | 2.3 ± 0.9 (0–6) |
| Female | 159 (94) | 85 (97) | 22 (92) | 21 (100) | 9 (100) | 15 (75) | 7 (100) |
| Male | 10 (6) | 3 (3) | 2 (8) | 0 (0) | 0 (0) | 5 (25) | 0 (0) |
| Active chemotherapy number (%) | |||||||
| Yes | 47 (28) | 23 (26) | 5 (21) | 7 (33) | 2 (22) | 10 (50) | 0 (0) |
| No | 122 (72) | 65 (74) | 19 (79) | 14 (67) | 7 (78) | 10 (50) | 7 (100) |
| Active anti-hormonal therapy number (%) | |||||||
| Yes | 82 (48) | 45 (51) | 11 (46) | 9 (43) | 4 (44) | 8 (40) | 5 (71) |
| No | 87 (52) | 43 (49) | 13 (54) | 12 (57) | 5 (56) | 12 (60) | 2 (29) |
| Radiation therapy number (%) | |||||||
| Completed | 69 (41) | 27 (31) | 14 (58) | 12 (57) | 5 (56) | 8 (40) | 3 (43) |
| None | 97 (57) | 58 (66) | 10 (42) | 9 (43) | 4 (44) | 12 (60) | 4 (57) |
| Active | 3 (2) | 3 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Surgical procedure number (%) | |||||||
| Completed | 158 (93) | 83 (94) | 22 (92) | 21 (100) | 7 (78) | 18 (90) | 7 (100) |
| None | 8 (5) | 3 (3) | 1 (4) | 0 (0) | 2 (22) | 2 (10) | 0 (0) |
| Pending | 3 (2) | 2 (2) | 1 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Cancer diagnosis number (%) | |||||||
| Breast | 149 (87) | 83 (94) | 20 (83) | 19 (90) | 7 (78) | 13 (65) | 7 (100) |
| Gastrointestinal | 6 (4) | 2 (2) | 1 (4) | 1 (5) | 1 (11) | 1 (5) | 0 (0) |
| Head and neck | 6 (4) | 2 (2) | 2 (8) | 0 (0) | 0 (0) | 2 (10) | 0 (0) |
| Genitourinary | 4 (2) | 0 (0) | 1 (4) | 0 (0) | 0 (0) | 3 (15) | 0 (0) |
| Hematopoietic | 3 (2) | 1 (1) | 0 (0) | 0 (0) | 1 (11) | 1 (5) | 0 (0) |
| Lung | 1 (1) | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 0 (0) | 0 (0) |
| Distant metastasesc number (%) | |||||||
| Yes | 16 (9) | 7 (8) | 1 (4) | 2 (10) | 0 (0) | 6 (30) | 0 (0) |
| No | 153 (91) | 81 (92) | 23 (96) | 19 (90) | 9 (100) | 14 (70) | 7 (100) |
aAge at clinic presentation: at pace vs. slower self-paced p = 0.0155, at pace vs. shorter self-paced p < 0.0001, at pace vs. flat self-paced p < 0.0001, at pace vs. contraindicated p = 0.0015, one-way ANOVA, Tukey's multiple comparisons test.
bAge at diagnosis: at pace vs. slower self-paced p = 0.0371, at pace vs. shorter self-paced p < 0.0001, at pace vs. flat self-paced p < 0.0001, at pace vs. contraindicated p = 0.0015, one-way ANOVA, Tukey's multiple comparisons test.
cDistant metastases: at pace vs. contraindicated p = 0.0142, Fisher's exact, two-tailed. SEM: standard error of the mean.